Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Five Prime Therapeutics, Inc.”

67 pharma patents match "Five Prime Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 67
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 67 pharmaceutical patents matching "Five Prime Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

67 results for “Five Prime Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12365719

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Five Prime Therapeutics, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  2. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Five Prime Therapeutics, Inc. · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  3. US 12195535

    Antibodies binding to VISTA at acidic pH

    Five Prime Therapeutics, Inc. · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  4. US 12173069

    Antibodies binding to vista at acidic pH

    Five Prime Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  5. US 12091462

    Antibodies binding to vista at acidic pH

    Five Prime Therapeutics, Inc. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  6. US 11975046

    Medical use of interferon-lambda for the treatment of fibrosis

    Five Prime Therapeutics, Inc. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  7. US 11939383

    B7-H4 antibodies and methods and use thereof

    Five Prime Therapeutics, Inc. · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  8. US 11814431

    B7-H4 antibodies and methods of use thereof

    Five Prime Therapeutics, Inc. · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  9. US 11603406

    Antibodies binding to VISTA at acidic pH

    Five Prime Therapeutics, Inc. · Granted Mar 14, 2023 · Expires Mar 9, 2043

    granted
  10. US 11566076

    Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

    Five Prime Therapeutics, Inc. · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  11. US 11559583

    Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted
  12. US 11421034

    Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

    Five Prime Therapeutics, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  13. US 11401328

    Antibodies binding to ILT4

    Five Prime Therapeutics, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted
  14. US 11306150

    Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist

    Five Prime Therapeutics, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  15. US 11306144

    B7-H4 antibodies and methods of use thereof

    Five Prime Therapeutics, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  16. US 11235059

    Afucosylated anti-FGFR2IIIB antibodies

    Five Prime Therapeutics, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted
  17. US 11186646

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  18. US 11098103

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Five Prime Therapeutics, Inc. · Granted Aug 24, 2021 · Expires Aug 19, 2041

    granted
  19. US 11091555

    Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy

    Five Prime Therapeutics, Inc. · Granted Aug 17, 2021 · Expires Aug 12, 2041

    granted
  20. US 10982001

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  21. US 10975153

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  22. US 10822421

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted
  23. US 10799559

    NOPE for treatment of pathological muscle loss and weakness

    Five Prime Therapeutics, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted
  24. US 10730949

    Method of treating PVNS with anti-CSF1R antibodies

    Five Prime Therapeutics, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted